| Anaemia | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Coagulopathy | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eosinophilia | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Lymphadenitis | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Neutropenia | Blood and lymphatic system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Arrhythmia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Bradycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Bundle branch block right | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cardiac failure | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Cardiomyopathy | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Defect conduction intraventricular | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Diastolic dysfunction | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Heart valve incompetence | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Left ventricular dysfunction | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pericardial effusion | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Right atrial dilatation | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Right ventricular hypertrophy | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sinus bradycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sinus tachycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Supraventricular tachycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Tachycardia | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG00013 affected113 at risk
|
| Tricuspid valve incompetence | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Wolff-Parkinson-White syndrome | Cardiac disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Cryptorchism | Congenital, familial and genetic disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cerumen impaction | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Conductive deafness | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Deafness | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Deafness neurosensory | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Deafness unilateral | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ear pain | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Eustachian tube dysfunction | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Middle ear effusion | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Mixed deafness | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Otorrhoea | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Tympanic membrane disorder | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tympanic membrane perforation | Ear and labyrinth disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Precocious puberty | Endocrine disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Astigmatism | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Blepharitis | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Chalazion | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Conjunctival hyperaemia | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Dry eye | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Eye discharge | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye irritation | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye pruritus | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye swelling | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eyelid oedema | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eyelid ptosis | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Hypermetropia | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lid sulcus deepened | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Myopia | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Ocular hyperaemia | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Photophobia | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Strabismus | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Vision blurred | Eye disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Abdominal distension | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Abdominal pain | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00010 affected113 at risk
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00011 affected113 at risk
|
| Abnormal faeces | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Anal fissure | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Aphthous stomatitis | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00020 affected113 at risk
|
| Dental caries | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Dental discomfort | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00055 affected113 at risk
|
| Dysphagia | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Faecal incontinence | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Faeces discoloured | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Flatulence | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Frequent bowel movements | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastric ulcer | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastritis | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Gastrointestinal disorder | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Gingival bleeding | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Haematochezia | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Haemorrhoids | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ileus | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Infrequent bowel movements | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lip blister | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lip ulceration | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Mouth ulceration | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nausea | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00012 affected113 at risk
|
| Oral disorder | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Rectal fissure | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Regurgitation | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Retained deciduous tooth | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Retching | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Salivary hypersecretion | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Sensitivity of teeth | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Teething | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Tongue spasm | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tooth deposit | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tooth impacted | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Toothache | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Vomiting | Gastrointestinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00042 affected113 at risk
|
| Abasia | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Asthenia | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Catheter site erythema | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site extravasation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Catheter site haemorrhage | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site inflammation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site oedema | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site pain | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Catheter site rash | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site related reaction | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Catheter site swelling | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Chest discomfort | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Chest pain | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Chills | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Crepitations | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Device breakage | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Device dislocation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Device issue | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Device malfunction | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0009 affected113 at risk
|
| Device occlusion | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG00013 affected113 at risk
|
| Discomfort | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Disease progression | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Energy increased | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Extravasation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Fatigue | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Feeling hot | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gait disturbance | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Granuloma | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Gravitational oedema | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Influenza like illness | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Infusion site extravasation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Infusion site swelling | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Injection site extravasation | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Injection site swelling | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Malaise | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Oedema | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Oedema peripheral | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Pain | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Peripheral swelling | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Pyrexia | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG00061 affected113 at risk
|
| Secretion discharge | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Thirst | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Thrombosis in device | General disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hepatic fibrosis | Hepatobiliary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Drug hypersensitivity | Immune system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Food allergy | Immune system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hypersensitivity | Immune system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Multiple allergies | Immune system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Seasonal allergy | Immune system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Abscess limb | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Acarodermatitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Adenovirus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Atypical pneumonia | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Bacterial tracheitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Beta haemolytic streptococcal infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Body tinea | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Bronchiolitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Bronchitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0008 affected113 at risk
|
| Candida infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cellulitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Chronic sinusitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Clostridium difficile colitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Conjunctivitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Croup infectious | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Device related infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ear infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00012 affected113 at risk
|
| Ear lobe infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Enterovirus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Erythema infectiosum | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Escherichia urinary tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Folliculitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Fungal infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Fungal skin infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Furuncle | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastroenteritis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00011 affected113 at risk
|
| Gastroenteritis norovirus | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastroenteritis viral | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Gastrointestinal infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gingival abscess | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gingivitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Haemophilus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hand-foot-and-mouth disease | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Herpes zoster | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hordeolum | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Impetigo | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Influenza | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0008 affected113 at risk
|
| Labyrinthitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lice infestation | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lip infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Lobar pneumonia | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nail infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nasopharyngitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00012 affected113 at risk
|
| Oral candidiasis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Oral herpes | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Otitis externa | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Otitis externa fungal | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Otitis media | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00023 affected113 at risk
|
| Otitis media acute | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Otitis media chronic | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Pharyngitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Pharyngitis streptococcal | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00013 affected113 at risk
|
| Pneumonia | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00017 affected113 at risk
|
| Pneumonia viral | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pseudomonas infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Rash pustular | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Respiratory syncytial virus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Respiratory tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Rhinitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Rhinovirus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Rotavirus infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sinusitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Skin infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Staphylococcal infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Stoma site infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Streptococcal infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Streptococcal urinary tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Subcutaneous abscess | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tinea infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tonsillitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tooth abscess | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tooth infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tracheitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Tracheobronchitis | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tracheostomy infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00049 affected113 at risk
|
| Upper respiratory tract infection bacterial | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00019 affected113 at risk
|
| Viral infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG00015 affected113 at risk
|
| Viral rash | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Viral upper respiratory tract infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Vulvovaginal mycotic infection | Infections and infestations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Agitation postoperative | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Animal bite | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Animal scratch | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Arthropod bite | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Concussion | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Contusion | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Exposure to communicable disease | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye contusion | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eye injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Face injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Fall | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG00011 affected113 at risk
|
| Feeding tube complication | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Femur fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Foreign body | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastrointestinal anastomotic leak | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastrointestinal stoma complication | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hand fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Head injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Laceration | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Laryngeal injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ligament sprain | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Limb injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Lower limb fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Overdose | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Periorbital haemorrhage | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Post procedural haemorrhage | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Postoperative fever | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Postoperative respiratory distress | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Procedural nausea | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0008 affected113 at risk
|
| Procedural vomiting | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Scratch | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Skin abrasion | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0009 affected113 at risk
|
| Skin wound | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Soft tissue injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Splinter | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Stoma site erythema | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Stoma site haemorrhage | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Stoma site irritation | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Stoma site rash | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Stoma site reaction | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sunburn | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Thermal burn | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tibia fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tooth avulsion | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tooth fracture | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tooth injury | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tracheostomy malfunction | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Vaccination complication | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Wound | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Alanine aminotransferase abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Alanine aminotransferase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Aspartate aminotransferase abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Aspartate aminotransferase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Atrial pressure increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood alkaline phosphatase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood creatine phosphokinase MB increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Blood creatine phosphokinase abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood creatine phosphokinase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Blood culture positive | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood lactate dehydrogenase abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood lactate dehydrogenase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Blood potassium decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Blood pressure decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Blood pressure increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Blood pressure systolic increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood uric acid decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood uric acid increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Blood zinc decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Body temperature increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Brain natriuretic peptide increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Breath sounds abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Creatine urine increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Creatinine urine increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Electrocardiogram PR shortened | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Electrocardiogram QT prolonged | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Electrocardiogram ST segment elevation | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Electrocardiogram abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Eosinophil count increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Haematocrit decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Haemoglobin decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Heart rate increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Liver function test abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Neutrophil count abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Neutrophil count increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Neutrophil percentage increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Occult blood positive | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Oxygen saturation decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Platelet count increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Protein urine | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Protein urine present | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pulmonary function test decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Pulse pressure abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Respiratory rate increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Serum ferritin decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Specific gravity urine | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sputum culture positive | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Staphylococcus test positive | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tuberculin test positive | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urine ketone body present | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urine output decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Weight decreased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Weight increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| White blood cell count abnormal | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| White blood cell count increased | Investigations | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Abnormal weight gain | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Dehydration | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Electrolyte imbalance | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Failure to thrive | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hypochloraemia | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Iron deficiency | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Vitamin D deficiency | Metabolism and nutrition disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Arthropathy | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Axillary mass | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Deformity thorax | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Foot deformity | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Fracture pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hip deformity | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Joint contracture | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Joint stiffness | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Joint swelling | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Kyphosis | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Limb discomfort | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Muscle contracture | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Muscle spasms | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Muscle tightness | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Muscular weakness | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG00012 affected113 at risk
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Musculoskeletal pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Musculoskeletal stiffness | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Myopathy | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Osteopenia | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG00016 affected113 at risk
|
| Pain in jaw | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Scoliosis | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Tendinous contracture | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tendon discomfort | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Tendon disorder | Musculoskeletal and connective tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Allodynia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Areflexia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Burning sensation | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Clumsiness | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Convulsion | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Dizziness | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Facial paresis | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Formication | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gross motor delay | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Headache | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG00014 affected113 at risk
|
| Hypoaesthesia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hyporeflexia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Hypotonia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Lethargy | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Motor developmental delay | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Motor dysfunction | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Muscle contractions involuntary | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nystagmus | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Paraesthesia | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Paralysis flaccid | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Poor quality sleep | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Presyncope | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Psychomotor hyperactivity | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Somnolence | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Speech disorder | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tremor | Nervous system disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Aggression | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Agitation | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Anxiety | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Attention deficit/hyperactivity disorder | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Bruxism | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Insomnia | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Irritability | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Mental disorder | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Mood swings | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Oppositional defiant disorder | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sleep disorder | Psychiatric disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Dysuria | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Haematuria | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Incontinence | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pollakiuria | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Proteinuria | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urinary hesitation | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urinary incontinence | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Urinary retention | Renal and urinary disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Genital discomfort | Reproductive system and breast disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Vaginal prolapse | Reproductive system and breast disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Vulvovaginal disorder | Reproductive system and breast disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Vulvovaginal erythema | Reproductive system and breast disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Vulvovaginal pruritus | Reproductive system and breast disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Adenoidal hypertrophy | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Bronchial hyperreactivity | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Bronchial secretion retention | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Bronchial wall thickening | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Bronchomalacia | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Choking | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00036 affected113 at risk
|
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0006 affected113 at risk
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Hypercapnia | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hypoventilation | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Increased bronchial secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Increased upper airway secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Increased viscosity of bronchial secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00016 affected113 at risk
|
| Nasal discharge discolouration | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Nasal dryness | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00013 affected113 at risk
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Productive cough | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Pulmonary artery dilatation | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pulmonary congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0008 affected113 at risk
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Respiratory muscle weakness | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Respiratory tract congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Respiratory tract haemorrhage | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG00024 affected113 at risk
|
| Rhonchi | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Sneezing | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Snoring | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sputum discoloured | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Sputum increased | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tachypnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Throat irritation | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Throat tightness | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Tonsillar hypertrophy | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Tracheal ulcer | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Upper respiratory tract congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0008 affected113 at risk
|
| Upper-airway cough syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Use of accessory respiratory muscles | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Acne | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Blister | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Cold sweat | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Dermatitis | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0003 affected113 at risk
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Dermatitis diaper | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Dry skin | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Ecchymosis | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Excessive granulation tissue | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Granuloma skin | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Hyperkeratosis | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ingrowing nail | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ingrown hair | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Macule | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Mechanical urticaria | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Papule | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Petechiae | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Photosensitivity reaction | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Pruritus generalised | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG00031 affected113 at risk
|
| Rash erythematous | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Rash macular | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Rash pruritic | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Red man syndrome | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Seborrhoeic dermatitis | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Skin disorder | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Skin exfoliation | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Skin hyperpigmentation | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0004 affected113 at risk
|
| Skin lesion | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Swelling face | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA 17.1 | Systematic Assessment | | - EG0009 affected113 at risk
|
| Central venous catheterisation | Surgical and medical procedures | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Ear tube removal | Surgical and medical procedures | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Gastrostomy tube removal | Surgical and medical procedures | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Aortic dilatation | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Flushing | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0007 affected113 at risk
|
| Haematoma | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Hypertension | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0005 affected113 at risk
|
| Hypotension | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0002 affected113 at risk
|
| Pallor | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|
| Peripheral coldness | Vascular disorders | MedDRA 17.1 | Systematic Assessment | | - EG0001 affected113 at risk
|